eb3 yfp plasmid (Sartorius AG)
Sartorius AG is a verified supplier 
Sartorius AG manufactures this product 
86
Structured Review
Sartorius AG
eb3 yfp plasmid
Eb3 Yfp Plasmid, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eb3+yfp+plasmid/pm31735573-219-5-10
Average 86 stars, based on 1 article reviews
Eb3 Yfp Plasmid, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eb3+yfp+plasmid/pm31735573-219-5-10
Average 86 stars, based on 1 article reviews
eb3 yfp plasmid - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Transfection:Article Title: Isoquinoline-based biaryls as a robust scaffold for microtubule inhibitors. Article Snippet: We here report the discovery of isoquinoline-based biaryls as a new scaffold for colchicine domain tubulin inhibitors.. Colchicinoid inhibitors offer highly desirable cytotoxic and vascular disrupting bioactivities, but their further development requires improving in vivo robustness and tolerability: properties that both depend on the scaffold structure employed.. We have developed isoquinoline-based biaryls as a novel scaffold for high-potency tubulin inhibitors, with excellent robustness, druglikeness, and facile late-stage structural diversification, accessible through a tolerant synthetic route. Plasmid Preparation:Article Title: Isoquinoline-based biaryls as a robust scaffold for microtubule inhibitors. Article Snippet: We here report the discovery of isoquinoline-based biaryls as a new scaffold for colchicine domain tubulin inhibitors.. Colchicinoid inhibitors offer highly desirable cytotoxic and vascular disrupting bioactivities, but their further development requires improving in vivo robustness and tolerability: properties that both depend on the scaffold structure employed.. We have developed isoquinoline-based biaryls as a novel scaffold for high-potency tubulin inhibitors, with excellent robustness, druglikeness, and facile late-stage structural diversification, accessible through a tolerant synthetic route. |